Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Verrica Pharmaceuticals ( (VRCA) ).
On March 31, 2025, Verrica Pharmaceuticals Inc. appointed Dr. Gavin Corcoran as a Class I director, with his term expiring at the 2025 annual meeting of stockholders. Dr. Corcoran, who has extensive experience in the pharmaceutical industry, will receive stock options and an annual retainer as part of his compensation, aligning with the company’s policy for non-employee directors.
More about Verrica Pharmaceuticals
YTD Price Performance: -40.0%
Average Trading Volume: 381,937
Technical Sentiment Signal: Buy
Current Market Cap: $40.59M
For a thorough assessment of VRCA stock, go to TipRanks’ Stock Analysis page.